Atopic Dermatitis

Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.

Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.

Data from the RELIEVE-AD study show long-term control and treatment satisfaction.

Panelists share parting advice and key takeaways on the optimal management of atopic dermatitis within the treatment landscape.

Experts share insight on the challenges inherent in treating patients with atopic dermatitis despite recent advances in therapy.

A recent study aimed to identify whether using specific serum biomarkers could predict therapeutic response in patients with atopic dermatitis.

Concluding their focused discussion on JAK inhibitors in atopic dermatitis, panelists share advice on the optimal selection based on route of administration and use of these agents.

A brief review of 2 oral JAK inhibitors recently approved for patients with atopic dermatitis.

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.

Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.

Drs James Q. Del Rosso and Neal Bhatia explain how to manage patients who fail therapy and provide safety considerations when treating those patients.

What is the relationship between mental disorders and atopic dermatitis? Investigators from a recent study endeavored to find out.

Experts discuss newly approved oral JAK inhibitors for the treatment of atopic dermatitis.

A review of topical JAK inhibitor ruxolitinib.

The American Academy of Dermatology’s newest guideline focuses on awareness of other health conditions associated with atopic dermatitis in adult patients.

If approved, dupilumab will be the first biologic medicine available in the US to treat uncontrolled moderate to severe atopic dermatitis for young children 6 months to 5 years old.

Click to answer this week's poll on the newly released AAD guidelines on AD comorbidites.

James Q. Del Rosso, DO, and Neal Bhatia, MD, provide an overview of JAK inhibitors for the treatment of atopic dermatitis.

A retrospective cohort study in a research letter published in the Journal of the American Academy of Dermatology examined the risk between atopic dermatitis and COVID-19 risk.

A long-term study of 2 British cohorts with atopic dermatitis (AD) reveals 4 distinct disease patterns occurring between birth and midlife.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Patients suffering from a wide range of dermatologic diseases can benefit from the new and exciting therapies and treatment modalities that have recently become available.

Neal Bhatia, MD, highlights the most exciting new drugs and therapies in atopic dermatitis and psoriasis in his presentation at the current Maui Derm for Dermatologists meeting.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

One of the key differences between diagnosing AD in patients with skin of color compared to White skin is erythema.

Click here to answer this week's poll.